LFD-200 / Lifordi Immunotherapeutics - LARVOL DELTA

LFD-200, an Antibody Drug Conjugate That Selectively Delivers a Glucocorticoid to Immune Cells, has Anti-Inflammatory Activity and was Well Tolerated Without Systemic Side Effects in an Ongoing Phase 1 Study (ACR Convergence 2026) - No abstract available

ADC • Adverse events • Immune cell • P1 data • Immunology • Rheumatoid Arthritis • Rheumatology

Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026 (Newsfile) - "Initial Phase 1 data in showed LFD-200 was safe and well tolerated, and demonstrated anti-inflammatory effects without affecting cortisol; Dosing in the Phase 1 study of LFD-200 in patients with Rheumatoid Arthritis is ongoing, with data expected by year-end 2026; First-in-human clinical data for LFD-200 was presented in a poster presentation at EULAR 2026."

First-in-human • P1 data • Trial status • Rheumatoid Arthritis

LFD-200, an Immune-Targeted Glucocorticoid ADC, Demonstrates a Favorable Safety, PK, and PD Profile vs. Prednisone and Placebo in a First-in-Human Study (EULAR 2026) - "The observed lack of systemic toxicity, including no suppression of cortisol, justifies continued evaluation in HPs and, subsequently, patients with RA. These data also indicate that the targeted delivery of a GC payload to immune cells via LFD-200 has a favorable risk profile vs. systemically available GCs."

ADC • Clinical • First-in-human • P1 data • Immunology • Infectious Disease • Inflammatory Arthritis • Respiratory Diseases • Rheumatoid Arthritis

LFD200A11: A study to find how safe different doses of LFD-200 are and how it works in both healthy people and people with moderate to severe rheumatoid arthritis (clinicaltrialsregister.eu) - P1 | N=40 | Not yet recruiting | Sponsor: Lifordi Immunotherapeutics Inc.

New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Lifordi Immunotherapeutics Secures $112 Million Investment to Advance Autoimmune Disease Treatment (City Buzz) - "The investment will support the ongoing Phase 1 study evaluating LFD-200, an ADC designed to deliver a potent glucocorticoid directly to immune cells. The funding also provides for Chemistry Manufacturing and Controls preparations to ensure Phase 2 clinical supply availability without unnecessary delays."

Financing • Rheumatoid Arthritis

Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - P1 | N=176 | Recruiting | Sponsor: Lifordi Immunotherapeutics, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Lifordi Immunotherapeutics Presents Nonclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 at ACR 2025 and Initiates Phase 1 Study in Rheumatoid Arthritis (Yahoo Finance) - "LFD-200 achieves sustained GC exposures in immune cells of non-human primates and suppresses proinflammatory cytokine expression without evidence of toxicity; Phase 1 study of LFD-200 in Rheumatoid Arthritis is underway with initial data from healthy participants anticipated by year-end 2025."

Preclinical • Trial status • Rheumatoid Arthritis

LFD-200, an Antibody Drug Conjugate that Selectively Delivers a Glucocorticoid Payload to Immune Cells, Provides Sustained Anti-inflammatory Effects Without Systemic Toxicity in Non-human Primates (ACR Convergence 2025) - "The control group received one dose of vehicle followed by 2 doses of dexamethasone (Dex; 3 mg/kg) given 6 and 7 days post vehicle. In these NHP studies, LFD-200 selectively delivered sustained GC levels in immune tissues, resulting in inhibition of ex vivo induced inflammatory cytokines without evidence of systemic toxicity. LFD-200 has the potential to provide a safer, less frequently dosed GC treatment option for patients living with autoimmune or inflammatory diseases."

Immune cell • Asthma • Diabetes • Immunology • Inflammation • Metabolic Disorders • Respiratory Diseases • Rheumatology • IL1B • TNFA